scispace - formally typeset
B

Bruce E. Blough

Researcher at Research Triangle Park

Publications -  173
Citations -  5102

Bruce E. Blough is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Dopamine & Monoamine neurotransmitter. The author has an hindex of 36, co-authored 161 publications receiving 4479 citations. Previous affiliations of Bruce E. Blough include St. Joseph's Hospital and Medical Center & RTI International.

Papers
More filters
Journal ArticleDOI

3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) Induces Fenfluramine-Like Proliferative Actions on Human Cardiac Valvular Interstitial Cells in Vitro

TL;DR: It is found that long-term MDMA use could lead to the development of fenfluramine-like VHD, and the necessity of screening current and future drugs at h5-HT2B receptors for agonist actions before their use in humans is underscored.
Journal ArticleDOI

N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy').

TL;DR: The results show that BZP/TFMPP and MDMA share the ability to evoke monoamine release, but dangerous drug–drug synergism may occur when piperazines are coadministered at high doses.
Journal ArticleDOI

Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors.

TL;DR: The results suggest that clinical and behavioral effects of bupropion arise from actions at nAChR as well as DA and NE transporters and that the (2S,3S)-hydroxybupropion isomer may be a better drug candidate for smoking cessation because of its higher potency at the relevant targets.
Journal ArticleDOI

Relationship between the Serotonergic Activity and Reinforcing Effects of a Series of Amphetamine Analogs

TL;DR: The results suggest that the mechanism for this effect involves a decrease in reinforcing potency and efficacy among monoamine releasing agents when 5-HT releasing potency is increased relative to DA.
Journal ArticleDOI

Pharmacology of novel synthetic stimulants structurally related to the “bath salts” constituent 3,4-methylenedioxypyrovalerone (MDPV)

TL;DR: Findings represent the first evidence that second generation analogs of MDPV are catecholamine-selective uptake blockers which may pose risk for addiction and adverse effects in human users.